Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Basket Study of Brigatinib in Patients with Advanced Solid Tumors with ROS1 Rearrangement

Trial Profile

Basket Study of Brigatinib in Patients with Advanced Solid Tumors with ROS1 Rearrangement

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brigatinib (Primary)
  • Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms Barossa study
  • Sponsors Takeda Pharma

Most Recent Events

  • 13 Sep 2022 Primary endpoint has been met (objective response rate) , Results presented at the 47th European Society for Medical Oncology Congress
  • 13 Sep 2022 Results (n=28) reporting efficacy and data from cohort 1 of this trial in which TKI-naive ROS1-rearranged NSCLC patients were enrolled presented at the 47th European Society for Medical Oncology Congress
  • 14 Sep 2021 Results (n=19) of cohort 2 were presented at the 2021 World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top